Oticara Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 5

Oticara General Information

Description

Developer of a biopharmaceutical therapy designed to treat chronic rhinosinusitis through targeted intranasal delivery. The company's therapy offers physician-administered localized corticosteroid delivery, semisolid formulation for sustained mucosal contact, and single-dose application with reduced systemic exposure, enabling physicians to treat patients with persistent sinus conditions and improve symptom control through targeted care.

Contact Information

Website
www.oticara.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12319 North Mopac Expressway
  • Suite 300
  • Austin, TX 78758
  • United States
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 12319 North Mopac Expressway
  • Suite 300
  • Austin, TX 78758
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oticara Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Clinical Trials - Phase 2
1. Seed Round 15-May-2022 Completed Clinical Trials - Phase 2
To view Oticara’s complete valuation and funding history, request access »

Oticara Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 2
Seed 1
Founders 2,603,466 $0.000100 $0.44 $0.44 1x $0.44 0%
To view Oticara’s complete cap table history, request access »

Oticara Patents

Oticara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021334325-A1 Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation Pending 26-Aug-2020
EP-4203958-A1 Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation Pending 26-Aug-2020
EP-4203958-A4 Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation Pending 26-Aug-2020
WO-2022047042-A1 Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation Inactive 26-Aug-2020
CA-3190833-A1 Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation Pending 26-Aug-2020 A61K9/06
To view Oticara’s complete patent history, request access »

Oticara Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oticara Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Healthcare Equity Angels Angel Group Minority
K20 Fund PE/Buyout Minority
Keiretsu Capital Venture Capital Minority
Keiretsu Forum Angel Group Minority
Springbok Ventures Venture Capital Minority
To view Oticara’s complete investors history, request access »

Oticara FAQs

  • When was Oticara founded?

    Oticara was founded in 2017.

  • Where is Oticara headquartered?

    Oticara is headquartered in Austin, TX.

  • What is the size of Oticara?

    Oticara has 5 total employees.

  • What industry is Oticara in?

    Oticara’s primary industry is Drug Discovery.

  • Is Oticara a private or public company?

    Oticara is a Private company.

  • What is Oticara’s current revenue?

    The current revenue for Oticara is .

  • How much funding has Oticara raised over time?

    Oticara has raised $5.9M.

  • Who are Oticara’s investors?

    Healthcare Equity Angels, K20 Fund, Keiretsu Capital, Keiretsu Forum, and Springbok Ventures have invested in Oticara.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process